Main text
Pseudouridylation is the most abundant post-transcriptional modification of RNA. 1; 2 Pseudouridine (5-ribosyluracil, Ψ) is the 5-ribosyl isomer of uridine. 1 It was the first modified nucleoside to be discovered in RNA and is found in transfer RNA (tRNA), 3; 4 small nuclear RNA (snRNA), 5 small nucleolar RNA (snoRNA), 1 ribosomal RNA (rRNA), 6; 7 and more recently also in messenger RNA (mRNA). [8] [9] [10] [11] RNA pseudouridylation can lead to a stabilization of the 3D structure of RNA 12; 13 by an altered RNA structure, 14 increased base stacking, 15 improved base-pairing 16 and a rigidified sugar-phosphate backbone. 17 Pseudouridylation in human is catalyzed by 13 pseudouridine synthases (PUSs), which are either guided to their targets via small nucleolar RNAs (snoRNAs), or directly recognize their targets in an RNA-independent manner. 1; 18 Variants in genes that code for RNA-independent pseudouridine synthases have been shown to result in a monogenic disorder. Recessively inherited PUS1 [MIM: 608109] pathogenic variants cause defective oxidative phosphorylation resulting in progressive mitochondrial myopathy and sideroblastic anemia (MLASA syndrome [MIM: 600462]). 19 In addition, growth delay, secondary microcephaly, and intellectual disability have been reported in multiple individuals. [20] [21] [22] [23] [24] Recently, a second pseudouridylation defect has been described in a single consanguineous family with a homozygous PUS3 [MIM: 616283] variant, another RNA independent pseudouridine synthase. 25 Affected family members have severe to profound intellectual disability, microcephaly, and severe growth deficiency. Both pseudouridine synthases modify tRNA at various positions, suggesting that reduced pseudouridylation of tRNA may cause progressive monogenic multisystemic diseases centered around a general failure to thrive and neurodevelopmental delay. PUS7 [MIM: 616261] encodes RNA-independent pseudouridylate synthase 7. Both yeast and human PUS7 recognize a UGΨAG core motif. 8; 26 Yeast PUS7 modifies U2 snRNA at position 35, 5; 8 several tRNAs at position 13, position 35 in pre-tRNA(Tyr), 27 and a large number of mRNAs, the latter in particular upon a heat shock. 8 Human PUS7 was shown to modify tRNAs and tRNA-derived small fragments (tRFs). 28 Pseudouridylation of tRFs is required for early embryogenesis and for hematopoiesis. In addition, human PUS7 targets dozens to hundreds of different mRNAs implicated in a range of functions. 8; 11; 26 Here, we describe six persons from three independent families with deleterious biallelic variants in Table 1 ) originates from Pakistan and has been described briefly before by Riazuddin et al. (2016) 29 as a family with moderate ID, speech delay and aggressive behavior (see Supplemental Note). The parents of the four affected siblings (IV2-5) are first cousins. The three affected individuals who are still alive (aged 7-18 years), presented with moderate intellectual disability, speech delay, and aggressive behavior. The two oldest siblings (IV-2 and IV-3) who were approachable for further evaluation also had short stature, low weight, and microcephaly. Pregnancy and delivery were uneventful and birth parameters within normal range for all affected family members. Family 2 (MR046; Fig. 1B; Table 1 ) stems from the Southern part of Syria. The parents are first degree cousins. They have two sons (IV-1 and IV-2) with a moderate intellectual disability, motor and speech delay (see Supplemental Note). The oldest sibling (IV-1) of 8 yearsold showed hyperactive, aggressive, and destructive behavior. Both siblings had short stature, and microcephaly. Weight was not determined at the time of investigation, but their BMI was visibly in the lower normal range. Pregnancies of both children were uneventful. However, the parents reported that at birth the elder boy had a small head, and that he seemed to be lifeless for the first 30 minutes after birth. The family is now lost for further follow-up.
Family 3 (R14-22173) is a consanguineous Dutch family of Moroccan descent in which one boy (II-2) has intellectual disability ( Fig. 1C; Table 1 ). At the age of three months, he presented with hypotonia and motor delay (see Supplemental Note). At the age of three years, he also presented with speech delay and aggressive behavior. His growth parameters were delayed as well as he had short stature, low weight, and microcephaly. Pregnancy and delivery were uneventful, however the neonatal period was complicated by feeding difficulties and hypopnea, requiring tube feeding and respiratory support for three weeks.
Exome sequencing was performed on DNA from one (Family 2 and 3) or two (Family 1) affected individuals from each of the three families. In family 1, a homozygous c.89_90del frameshift variant (p.(Thr30Lysfs*20)) was identified in PUS7 (GenBank: NM_019042.3; Fig.   S1A ). Sanger sequencing showed that his variant was homozygously present in the affected siblings, heterozygously in the parents, and absent in the unaffected sibling ( Fig. S1B) . This variant is predicted to result in nonsense-mediated mRNA decay. Accordingly, quantitative PCR (qPCR) analysis showed that PUS7 mRNA levels in Epstein Barr-Virus-transformed lymphoblastoid cell lines (EBV-LCLs) from family member IV-3 were 1.8-fold (P=0.036) reduced as compared to those in EBV-LCLs from healthy control individuals ( Fig. S2A) .
Western blot analysis confirmed the absence of a normally sized PUS7 protein in this affected individual ( Fig. S2B) .
In family 2, we performed homozygosity mapping 30 with the use of HomozygosityMapper 31 . After sequencing the index and evaluating the data as previously described 32 , a homozygous c.1348C>T nonsense variant (p.(Arg450*)) was identified in PUS7 ( Fig. S1A) . Both affected brothers carried this variant homozygously and the mother was a heterozygous carrier ( Fig. S1C) . Their father was not available for testing. This variant is also predicted to result in nonsense-mediated mRNA decay and qPCR analysis established that PUS7 mRNA levels in family member IV-1 were indeed 15.6-fold (P<0.0001) reduced as compared to those in controls ( Fig. S2A) .
In family 3, exome sequencing was performed on both the affected male individual and his parents. No potentially causative de novo, biallelic, or X-linked single nucleotide variants or indels were found. CNV analysis of the exome data of the affected individual indicated a potential deletion of the last two exons of PUS7, which had not been identified by the earlier-performed chromosomal microarray analysis, likely because of the small size of the deletion (max. 5kb). Multiplex amplification quantification analysis confirmed a homozygous deletion of only exon 15 in the affected individual ( Fig. S1D) . This deletion was heterozygously present in his father and absent in DNA from his brother. Genetic testing could not be performed in the mother. Reverse transcriptase PCR analysis confirmed that exon 15 was indeed absent from PUS7 mRNA (Fig. S1E) . The penultimate exon 15 of PUS7 comprises 92 bp. A deletion of this exon results in a frameshift removing the C-terminus of PUS7 including 56 amino acid residues of the TruD catalytic domain (Fig. S1A) . Since the resulting premature stop codon is positioned after the last exon-exon boundary, PUS7 mRNA from affected individuals is likely to escape nonsense-mediated RNA decay. Accordingly, PUS7 mRNA levels in EBV-LCLs from family member II-2 were normal ( Fig. S2A ). In addition, Western blot analysis confirmed the absence of a normally sized PUS7 protein in this affected individual (Fig. S2B) .
The phenotype of our six persons with a pathogenic PUS7 variant closely resembles that of the single family with a homozygous PUS3 variant (MRT55 [MIM: 617051]). 25 The three affected family members with a PUS3 variant also presented with intellectual disability, secondary microcephaly, and short stature. Additionally, coarse facial features, strabismus, gray sclera and extensive Mongolian spots were noted, which were not present in our affected individuals. Remarkably, persons with recessively inherited PUS1 variants have intellectual disability, microcephaly, and growth delay as well. [20] [21] [22] [23] [24] This indicates that these three syndromes are closely related and can be defined by neurodevelopmental and growth delay. PUS1, PUS3, and PUS7 are expressed in all tissues analyzed (Fig. S3 ). The milder phenotype in affected family members with deleterious PUS7 variants might be related to the lower overall average PUS7 expression levels as compared to PUS1 and PUS3. The relatively high PUS7 expression levels in cerebellum and tibial nerve support a more specific role for PUS7 in neurodevelopment.
In order to assess whether PUS7 activity on tRNAs was impacted in the affected individuals, we first performed radioactive primer extension experiments in the presence of carbodiimide (CMC) followed by alkali treatment using total RNA from EBV-LCLs of individual IV-3 from family 1, primary fibroblasts individual II-2 from family 3, and corresponding controls (Fig 2A; Fig S4) . This method relies on the ability of a CMC to form a covalent adduct with pseudouridine and to cause cDNA truncations upon reverse transcription, which can be quantified by primer extension. We detected a clear reduction in signal at Ψ13 in tRNAGlu in material from affected individuals as compared to controls. In order to more systematically investigate the activity of PUS7, we also performed unbiased pseudouridylation mapping using Ψ-seq. This method also relies on reverse transcription truncations induced by CMC, but is followed by sequencing all of the truncation sites in RNA.
This enables detection of the positions at which reverse transcriptase selectively dropped off upon treatment with CMC, compared to an untreated control. 8 We first applied Ψ-seq to total RNA extracted from four EBV-LCLs originating from controls, and two from affected individuals. Based on analysis of termination sites in CMC-treated samples in comparison to input, we assembled a dataset of 234 sites with consistent evidence of pseudouridylation across at least two of the samples, 161 of which (69%) originated from within tRNA molecules. We then performed a directed search for sites that underwent differential pseudouridylation between affected individuals and controls. Using strict criteria (both t-test p-value<0.05 and Chi-squared p-value<0.05), ten sites passed the threshold (Table S1 ).
Strikingly, all of these sites were at position 13 of various tRNAs, a position orthologous to the known Pus7 modification site in budding yeast. To expand this analysis, we classified the 161 sites detected in tRNAs into families on the basis of the position within the tRNA that was modified and the pseudouridine synthases putatively catalyzing their formation. The major families represented in our dataset included position 13 (n=17; putative PUS7 target), positions 27/28 (n=38; in yeast substrates of PUS1 33 ) and positions 38/39 (n=36; substrates of PUS3 34 ). This analysis revealed that the pseudouridylation signal in EBV-LCLs of affected individuals was essentially abolished at the PUS7 substrates at position 13, but not at the remaining positions ( Fig. 2B) . This confirms the specific abolishment of pseudouridine from position 13 of tRNAs within the two affected individuals harboring a variation in PUS7. To expand this analysis, we also conducted Ψ-seq on total RNA from primary fibroblasts of individual II-2 from family 3 including corresponding controls, and observed a significant reduction of signal from position 13 of tRNAs (p-value<0.05; Fig. S5 ).
Position 35 in yeast U2 snRNA was previously shown to undergo pseudouridylation via Pus7. 5; 8 We thus assessed whether pseudouridylation at its mammalian counterpart, in human at position 34 of U2 snRNA, was impacted in the affected individuals. However, we did not observe decreased pseudouridylation at this position (Fig. 2B) , most likely indicating that in human this modification is catalyzed via a different pseudouridine synthase. This is consistent with previous observations in Xenopus oocytes indicating that the pseudouridylation of this site is mediated by an H/ACA box small containing RNA. 35 In yeast, Pus7 also modifies position 35 in pre-tRNA(Tyr). 27 This position was insufficiently covered in our data, likely due to additional modifications on tRNA-Tyr that prevented efficient reverse transcription.
PUS7 has also been implicated in mRNA pseudouridylation. Therefore, we applied Ψseq to poly(A) enriched RNA derived from one affected individual and one control sample.
We then quantified pseudouridylation signals across a pre-defined high-confidence catalog of PUS7 sites in mRNA, as well as across TRUB1 targets serving as controls. 26 This catalog was filtered to retain only sites for which we had sufficient coverage in the experiments and which showed minimal evidence for pseudouridylation in our samples. We observed a decrease in pseudouridylation levels across these nine PUS7 targets in affected individuals compared to controls (paired t-test, p=0.003, n=9) whereas no changes were observed in TRUB1 targets (paired t-test, p=0.43, n=24) ( Fig. 2D,E ;Table S2 ). Thus, PUS7 activity is strongly reduced and likely eliminated within mRNA targets in affected individuals.
PUS7 variants identified in the three families thus result in aberrant pseudouridylation of at least ten cytosolic tRNAs at position 13. tRNAs are the main target of PUS7 as more than 70% of all PUS7-modified RNAs are tRNAs. 28 Both PUS1 and PUS3 also modify predominantly cytosolic tRNA at various positions, suggesting that aberrant tRNA pseudouridylation could be the common cause underlying neurodevelopmental and growth delay. The more severe phenotype of persons with PUS1 pathogenic variants consisting of MLASA syndrome 19 may be due to a dual role of PUS1 in modifying both cytosolic and mitochondrial tRNAs, in contrast to PUS7, which does not modify mitochondrial tRNAs. It is yet unknown whether PUS3 may pseudouridylate mitochondrial tRNAs. The pathogenicity of the PUS7 variants may also be partially mediated by the dysregulated mRNA pseudouridylation profile, but the functional relevance of pseudouridine on mRNA remains to be established.
Next, we knocked out the uncharacterized Pus7 homolog (CG6745) in Drosophila melanogaster to address whether PUS7 function is conserved across evolution. CG6745 is highly conserved between Drosophila and human with a DIOPT (Drosophila RNAi Screening
Center Integrative Ortholog Prediction Tool) score of 12, which means 12 out of the 15 tools to identify orthologs indicate that CG6745 is the human ortholog of PUS7. 36 Using the CRISPR/Cas9 approach, we generated a small deletion of 13 nucleotides in the first half of the gene, which leads to an early frameshift and a premature stop codon (Fig. 3A) . The resulting protein is expected to lack the entire Pus synthase domain.
As Pus7 mutant flies were viable, we proceeded by evaluating the effect of the variant on fly behavior by applying the Buridan's paradigm 37 . We found that the overall activity of Pus7 mutant flies was significantly increased (t-test analysis of variance with Bonferroni correction, p<0.001; Fig. 3B ). In addition, severe orientation defects were observed as evidenced by a significantly larger angular deviation (t-test analysis of variance with Bonferroni correction, p<0.01) of their 15-minutes walking traces ( Fig. 3C, 3D ). We obtained similar results when Pus7 mutants were crossed with a deficiency line deleting the Pus7 locus along with additional flanking genes, ruling out off-target effects. The increased activity of Pus7 mutant flies may indicate that hyperactive behavior of affected individual IV-1 from family 2 may be directly related to the PUS7 variants. As individuals with a PUS7 variant also exhibit aggressive behavior, we wondered whether this trait might be conserved in Drosophila. To address this possibility, we performed an aggression assay as described previously. 38 Briefly, single control and mutant adult males were placed in a small chamber containing food at its center. The two flies compete for the food and exhibit several fighting behaviors that can be quantified ( Fig. S6) . Overall, we found that Pus7 flies spent significantly more time fighting ( Fig. 3E) and were most often the winner of the fight (Fig.   3F ), indicating that they are more aggressive than their wild-type counterpart.
We next attempted to rescue the behavior defects by expressing Pus7 cDNA in the Pus7 mutant background. However, this experiment was inconclusive as overexpression of Pus7 in wild-type context already strongly alters fly activity and orientation ( Fig. S7) . Notably, expression of Pus7 only in neurons by using the Elav-GAL4 driver was sufficient to alter fly behavior, suggesting that Pus7 exerts its activity through a neuronal function. Altogether these findings demonstrate that Pus7 controls several aspects of fly behavior and that its dosage must be tightly regulated.
Lastly, we performed Ψ-seq analysis on total RNA derived either from wild-type or Pus7 mutant fly heads, and performed an unbiased search towards pseudouridylation sites deficient in the latter. Of 11 sites passing our thresholds, nine occurred at position 13 of diverse tRNAs ( Table S3 ), indicating that the molecular role of Pus7 is conserved between human and drosophila.
In conclusion, we describe a syndrome consisting of intellectual disability, speech delay, microcephaly, short stature, and aggressive behavior, which is caused by deleterious PUS7 variants. We demonstrate that the variants lead to a loss of PUS7 activity on both tRNA and mRNA substrates. A role for PUS7 in neurodevelopment is further corroborated by its relatively high expression levels in the brain and by Pus7 knockout Drosophila that display hyperactivity, disorientation, and aggressiveness, likely due to a defective nervous system.
Our findings strengthen the notion that RNA pseudouridylation and especially tRNA modification is essential for proper neuronal development. have microcephaly and short stature. Both affected siblings have abnormal dentition. Family member IV:2 has hypodontia and misaligned teeth while IV:3 has only misaligned teeth. In addition, both siblings have a smooth philtrum and an everted lower lip (Fig. 1A) . There were two other affected children in this family. A 10 year old affected male child, IV:4, of this family was adopted by their relatives and is not living with them anymore. The affected daughter IV:5 died at the age of five years of uncertain causes. He did not talk, and he showed aggressive (beats other children) and destructive behavior (destroying furniture of examination room). He permanently tried to provoke his parents and grandfather. Abdomen ultrasound showed that liver was mildly enlarged. Liver biopsy, bone age measurement and eye examination were unremarkable. Brain MRI revealed mild atrophy and enlargement of ventricles.
Figure legends
The pregnancy, birth and neonatal phase of the younger affected child (IV-2) was unremarkable. At the time of examination, he was two years old, was 80 cm tall (-2.2 SD), and had a head circumference of 46 cm (-2.5 SD). He could not walk, but he was sliding forward on his bum. He also did not talk. He had anemia and ferritin levels were decreased.
Both boys have some remarkable facial characteristics of long and smooth philtrum, thin lips with down-slanting palpebral fissures, and arched eyebrows (Fig. 1B) . None of the boys had epilepsy. Sleeping pattern, hearing and vision of both seemed to be unremarkable.
Family 3 (R14-22173)
Family 3 (R14-22173) is a consanguineous Dutch family of Moroccan descent in which one boy has intellectual disability ( Fig. 1C; Table 1 ). He has an older brother with speech delay only. The affected individual was born at 40+1 weeks of gestation to healthy consanguineous parents who were first cousins. Pregnancy was uneventful. The birth weight was 3440 grams and the APGAR score was 7 and 9 at 1 and 5 minutes after birth. The neonatal period was complicated by feeding difficulties and hypopnea, requiring tube feeding and respiratory support for three weeks. At three years and three months his height is 95.5 cm (-2.2 SD), weight 11.5 kg (-3.0 SD corrected for height), and head circumference 46.3 cm (-2.5 SD). There are no gross facial dysmorphisms, except for bilateral epicanthal folds, broad nasal root, full lips and eversion of lower lip and wide spaced conical shaped teeth (Fig. 1C) . He has clinodactyly digiti V of the hands and hyperlaxity in the thumbs. Feeding remains problematic. It is difficult to get him to eat. He refuses food and everything has to be mashed. Transcriptome data was retrieved from the Genotype-Tissue Expression (GTEx) project. 21 Levels are given in transcripts per million (TPM). Interactions specific for aggressive fly behavior evaluated for fights between wild-type Wing threatening is defined as raising both wing by a 45° angle. Chasing is characterized by a fly running after its opponent. For each substrate we list its genomic and transcriptomic coordinates, its gene symbol and strand, and a sequence of five bases centered around the putative pseudouridylation site. assessing the significance of the comparison between wild-type and deletion samples. We further provide the sequence surrounding the identified site.
Supplemental Methods

Exome sequencing & CNV analysis
Genomic DNA was isolated from peripheral blood samples following standard procedures. 3 Exome enrichment and high-throughput sequencing were performed at the Radboudumc (Nijmegen, the Netherlands), The Wellcome Trust Sanger Institute (Hinxton, UK; as part of the UK10K study), and the Institute of Human Genetics (Erlangen, Germany) as previously described. 2; 4 Copy number variant analysis was either performed on exome data by using Selection of biallelic potentially pathogenic variants was performed using seven major filtration steps as previously described. 4; 8 In case of family 3, a de novo analysis was performed as well by established procedures. 9
Sanger sequencing
Validation of variants and sequencing of the coding exons of PUS7 (GenBank: 
Multiplex amplification quantification
Multiplex amplification quantification (MAQ) was essentially performed as described by
Kumps et al. 10 Custom-made probes were designed for exons 14, 15, and 16. Their signal was compared to the average signal of six control probes located elsewhere in the genome of three healthy control individuals consisting of two women and one man. All probe sequences are available on request.
Quantitative and reverse transcriptase PCR analysis
Quantitative PCR (QPCR) analysis to assess nonsense-mediated mRNA decay of mutated PUS7 in human Epstein Barr-Virus-transformed lymphoblastoid cell lines (EBV-LCLs) and fibroblasts was performed as described before. 11 Reverse transcriptase PCR (RT-PCR) analysis was executed as described by Vulto-van Silfhout et al. (2015) . 12 
Western blot
A similar number of cells from different affected individuals were lysed using standard lysis buffer with protease inhibitor cocktail (Calbiochem, Merck KGaA, Darmstadt, Germany).
Proteins were separated using standard PAGE separation, transferred to a nitrocellulose membrane and detected by western blotting as described previously. 13 The following antibodies were used: anti-GAPDH (dilution 1∶2000; Sigma-Aldrich, Merck KGaA, Darmstadt, Germany), anti-PUS7 (dilution 1∶500; Sigma-Aldrich) and secondary HRP anti-rabbit/mouse from Jackson (dilution 1:10,000; ImmunoResearch, West Grove, PA, USA).
Transcriptome-wide pseudouridylation analysis
Total RNA was isolated from EBV-LCLs or from fibroblasts by using QIAzol according to the supplier's instructions (QIAGEN, Hilden, Germany). Ψ-seq was performed essentially as described previously. 14 Poly(A) enrichment was performed using Oligo(dT) dynabeads (Invitrogen) according to the manufacturer's protocol. Reads were mapped to the human genome using STAR aligner. 15 Putative Ψ sites in the first set of libraries used quantify pseudouridine on tRNAs were identified as described in Schwartz et al. 14 To compare across conditions, we first merged the positions of all windows passing step (2) from all samples, to define a set of all unique sites passing the filters in at least one condition.
For each such site, we then calculated a Ψ-ratio and Ψ-fc in each sample. (4) We then performed two statistical tests to assess the difference in pseudouridylation signal between affected individuals and controls. First, we aggregated the number of reads stopping or overlapping but not stopping at each putative position in affected individuals versus controls, and used this as a basis for a chi-squared test. Second, we performed a t-test, comparing the distribution of Ψ-ratio in affected individuals versus controls. Sites were considered significant if they matched all of the following criteria: (i) chi-squared and t-test p-values < 0.05, (ii) mean Ψ-ratio in the control >5%, and (iii) Mean Ψ-fc in the control exceeding 2.5. (5) From the final set of sites we excluded sites not harboring a 'T' at the identified position and eliminated redundant sequences, sharing a 21-bp sequence surrounding the putative target site, in order to retain only a single copy of redundant sequences such as identical tRNA copies. The sites passing these thresholds were also used to visualize Ψ-ratios across the four fibroblast-derived samples from one affected individual and three controls (Suppl. Fig.   4 ).
For the second set of libraries aiming to quantify pseudouridine on mRNA, an initial catalog of putative high-confidence pseudouridylation sites was obtained from Safra et al. 16 Specifically, we first identified all high confidence sites that were ranked in the two highest classes (classes 5 and 6), 16 based on which we assembled a set of 94 sites harboring a loosely defined TRUB1 motif (GUUC, bold U is the pseudouridylated motif) and 53 sites harboring a Pus7 motif (defined as U[G/A/C]UAG). We then quantified the Ψ-ratios at each of these sites across the two poly(A) libraries. To ensure adequate quantification and minimal evidence for pseudouridylation in our samples, we only retained sites covered by >15 reads across both samples, and harboring Ψ-ratios of >3% in at least one of the two samples. This resulted in nine and 25 sites, harboring PUS7 and TRUB1 consensus motifs, respectively.
We refer to all relative positions in tRNA based on the standard tRNA nomenclature so that the anticodon nucleotides are always numbered 34-36, and the T loop between positions 54 and 60.
Pseudouridylation analysis in Drosophila
To confirm that the targets of Pus7 pseudouridylation are conserved in Drosophila, we performed Ψ-seq on total RNA obtained from fly heads, with four replicates per wild-type and pus7 knockout samples. Two hundred ng of total RNA was used per condition. Reads were aligned against a database comprising a single copy of the drosophila rRNA, snRNA and tRNA sequences obtained from FlyBase. Unbiased pseudouridylation analyses were performed as above, with Ψ-ratio and Ψ-fc calculated for each position across each of the samples. t-test-based and chi-squared p-values were calculated for each site, comparing the four wild-type samples to pus7 knockout. Sites were considered as differentially pseudouridylated, if they met the following criteria: (1) Chi-squared p-value <0.05, (2) t-test pvalue <0.1, (3) Ψ-ratio in deletion samples <4%, and (4) difference between aggregated Ψratio in wild-type versus knock-out >3%. Drosophila pseudouridylation sequencing data was deposited in Gene Expression Omnibus (GEO), accession GSE121177.
Primer extension analysis
Total RNA extracted from lymphoblasts and fibroblasts was subjected to CMC/alkaline treatment followed by reverse transcription primer extension, as described previously. 17 The extended primer, 5'-GTGAGAGCGCCGAATCCTAACC-3', targets human cytoplasmic tRNA-Glu.
Buridan's behavioral paradigm analysis in Drosophila
Drosophila melanogaster Canton-S with a mutant allele for pus7 was generated using the CRISPR-Cas9 system, as described previously. 18 Guide RNAs sequences used were GTTTTTGGCCTTAGCCAGAT and GGAGTCGATTTTCAAGCGAA. A deletion of 13bp was produced from basepair 600 to 612 in the genome region chr3L:8,510,003-8,513,007
(genome assembly BDGP release 6) containing CG6745, the PUS7 Drosophila orthologue.
Behavioral tests were performed on five-day-old flies with Canton-S as wild-type control.
Wings were cut under cold anesthesia to one-third of their length on the evening before the experiment. Activity and orientation behavior was analyzed using Buridan's paradigm as described before. 19 All statistical groups were tested for normal distribution with the Shapiro-Wilk test. t-test analysis of variance with Bonferroni correction was used to compare different conditions. N=30 for all genotypes. Blinding was applied during the experiment. For the rescue experiment pus7 cDNA was cloned downstream of a UAS promoter and the plasmid was injected into fly embryos. Positive recombinants were isolated based on eye color as the plasmid also carries the white gene.
Aggression assay
A "handling free" behavior chamber described by Trannoy et al. (2015) 20 was used. Flies were constantly kept at 25°C. Male pupae were socially isolated. Aggression assay was applied on 6-day-old pairs of flies for 20 minutes. As food source apple juice agar with a drop of yeast was used. One day before analysis, flies were painted with acrylic ink during CO 2 anesthesia, since cold anesthesia leads to a decrease of aggressive behavior. Aggressive interactions including lunging, tussling, wing threat, boxing and chasing were evaluated for fights between wild-type Canton-S and homozygous pus7 fs flies. In addition, the fighting index (averaged total time spend fighting) and the winner status were scored. The winner of a fight keeps pushing the opponent from the food source, whereas the loser retreats.
